Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX).

Lexaria Bioscience Corp. (NASDAQ: LEXX) on July 22 announced it had met three primary objectives in its investigation of antiviral drug conversion process outcomes as the drugs are processed with its patented DehydraTECH(TM). “The success achieved during the company’s testing paves the way for larger analysis of the DehydraTECH-processed drugs in vivo in animals infected with SARS-CoV-2/COVID-19, HIV/AIDS, or other infectious disease-causing viruses, according to the company. The ultimate aim is to form partnerships with established pharmaceutical industry drug-makers who may be interested in incorporating DehydraTECH technology with those tested drugs, or other drugs with similar characteristics,” reads a recent article. “We are looking at repurposing some of these drugs, being able to take an antiviral drug that traditionally could only be administered, for example, by injection. We might be able to apply it in an oral form through a pill,” Lexaria CEO Chris Bunka told Investing News Network in a June report. “Our delivery from oral to the bloodstream is as little as two minutes. We’re outrageously fast for oral technology.” To view the full article, visit: https://cnw.fm/X2OVF

Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules. DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 19 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

• Speeds up delivery – the effects of the product are felt by the subject in just minutes.
• Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
• Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
• Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
• Reduces drug administration cost – lower doses mean lower overall drug costs.
• Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

• Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
• Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
• Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
• Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
• Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
• Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $6.09, up 1.5%, on 110,017 volume with 511 trades. The average volume for the last 3 months is 1.094M and the stock's 52-week low/high is $3.97510004/$12.50.

Recent News

• Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) - CannabisNewsBreaks - Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Technology Is 'Outrageously Fast' in Oral to Bloodstream Delivery
• Podcast Notes Blood Pressure Drug Delivery Trial Successes of Innovative Lexaria Bioscience Corp.'s (NASDAQ: LEXX) Technology
• Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented Technology Increasing Effectiveness and Potentially Lowering Healthcare Costs

AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (AMPG).

• Radio frequency (“RF”) technology designer and developer AmpliTech Group is leveraging this year’s Nasdaq uplisting and Russell Microcap Index placement to increase its market visibility
• AmpliTech builds and markets communications technology products for the satellite communications, space, telecommunications (5G/6G) and military defense markets 
• Markets analysts forecast continued growth over the next five years in the RF component sector, with a CAGR of 13 percent in the multi-billion-dollar sector
• AmpliTech reported a 2021 Q2 55% YOY revenue increase
• A recent follow-on order from an existing global defense and aerospace customer evidences AmpliTech’s growth potential as it continues to build revenues and strategically use its financial resources

The ever-present need for solutions that improve the speed and security of Internet-based technologies is exemplified in the rollout and evolution of 5G wireless communication capabilities worldwide. State-of-the-art RF signal component developer AmpliTech Group (NASDAQ: AMPG, AMPGW) has seen industry attention to its IP for satellite and 5G communications networks grow following its Nasdaq uplisting earlier this year and its more recent inclusion on the Russell Microcap Index in conjunction with the yearly reconstitution of the index, which took effect June 25. 

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:

Amplifiers

• Low Noise Amplifiers
• Cryogenic Amplifiers
• Limiting Amplifiers
• Waveguide Amplifiers
• Medium/High Power Amplifiers
• Surface Mount Amplifiers

Passive Components

• End Launch Rectangular Adapters
• Rectangular Adapter to COAX
• Power Dividers

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

• Timely technical assistance
• Little or no learning curve
• Less long-term costs associated with full-time employees with benefits and salaries
• Availability when necessary
• Customer support with schedules, project management and on the job training
• Access to technology
• Partnering for manufacturing and/or complete turn-key product solution
• Personal guidance from concept to development
• Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://nnw.fm/zqMEk). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://nnw.fm/rVzxX). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

• High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
• 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
• IoT (Internet of Things)
• Cloud Farms, Big Data and MEC architecture
• Quantum Supercomputers/Quantum Research
• Deep Space Astronomy
• Autonomous Self-Driving Vehicles
• Telemedicine, AR/VR (Augmented and Virtual Reality)
• Drones, UAVs (Unmanned Aerial Vehicles)
• Cyber-security
• Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Friday's trading session at $3.83, up 2.957%, on 83,991 volume with 501 trades. The average volume for the last 3 months is 256,680 and the stock's 52-week low/high is $0.879999995/$19.7999992.

Recent News

• AmpliTech Group Inc. (NASDAQ: AMPG) - AmpliTech Group Inc. (NASDAQ: AMPG) Poised for Anticipated Growth in RF Communications Tech Component Market
• AmpliTech Group Inc. (NASDAQ: AMPG) Secures Follow-on Order, Earns Russell Microcap(R) Index Inclusion
• InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Releases Q2 Revenue Report, Notes Key Numbers

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

• The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma
• InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants
• In addition to INM-088 for glaucoma, the company is currently working on CBN-based INM-755 to treat a rare genetic skin disorder called epidermolysis bullosa and is awaiting the answer to Phase II trial applications in various countries

Dedicated to delivering new therapeutic alternatives as a treatment for conditions with a high unmet medical need, InMed Pharmaceuticals (NASDAQ: INM) is leading the way as a clinical-stage company developing treatment alternatives using rare pharmaceutical-grade cannabinoids. The company’s operations and programs, in particular its ocular program, were the focus of a presentation given by InMed’s President and CEO Eric A. Adams and Senior Vice President of Pre-Clinical Research and Development Dr. Eric Hsu at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021 (https://cnw.fm/TbQ8f).

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.

Manufacturing

The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Friday's trading session at $2.44, up 3.8298%, on 37,535 volume with 261 trades. The average volume for the last 3 months is 71,673 and the stock's 52-week low/high is $2.01999998/$6.42000007.

Recent News

• InMed Pharmaceuticals Inc. (NASDAQ: INM) - InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference
• InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels
• BioMedNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Collaborate to Build Leading Rare Cannabinoid Company

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)

The QualityStocks Daily Newsletter would like to spotlight Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF).

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures, announced that it had secured a new convertible note totaling $3 million. Financing for the note, which was comprised of three tranches, was led by Rapha Capital BioVentures Fund I, LP (“RCBVFI”). The company anticipates using the funds  to support the clinical development of its lead product, the i/Blue(TM) Imaging System. According to the company, the proprietary system is poised to increase patient access to this important technology. In addition to the funding, Imagin Medical also named Kevin Slawin, MD, a leading uro oncologist and manager of RCBVFI, as a new board member. Slawin has cared for patients with cancer for more than 25 years and brings with him a deep knowledge of the field and of the needs of patients with prostate and bladder cancer. To view the full press release, visit https://ibn.fm/NtMUd

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging™ System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to visualize and remove cancer cells.

Founded in 2016 and headquartered in Boston, Massachusetts, the company works to enhance its market potential by expanding its technology to multiple endoscopic indications, such as laparoscopic, colorectal and thoracic procedures, accommodating multiple contrast agents and illumination sources.

i/Blue Imaging™ System

The conventional method used for visualizing bladder cancer during surgery is an endoscopic procedure called a cystoscopy. This procedure uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Blue light cystoscopy uses blue-filtered white light, which addresses the limitations of white light (such as detecting flat tumors and the fine edges that may result in cancerous cells being left behind during removal).

Blue light uses a contrast agent that causes cancer cells to fluoresce when illuminated. Surgeons are then able to more effectively visualize and resect the margins of bladder tumors to reduce the risk of recurrence. Notably, the use of the white light is still necessary during a blue-light procedure so that the surgeon can orient their position within the bladder.

Imagin Medical’s i/Blue Imaging System addresses the limitations of both white and blue light cystoscopies. The i/Blue System combines the white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.

The i/Blue Imaging System is unlike other methods available on the market today. It is external to the body and can attach to almost any endoscope model currently in use. This way, hospitals adopting Imagin Medical’s technology have the ability to use their current endoscopes without the need to purchase new equipment.

Bladder Cancer Prevalence

The company’s initial focus is bladder cancer, which is the sixth most prevalent form of cancer in the United States. In 2020, the number of new bladder cancer cases is expected to total 81,400, accounting for 4.5 percent of all new cancers diagnosed. The death rate in 2020 for cancer deaths associated with the bladder is forecast at 17,980, or 3% of all cancer-related deaths (https://ibn.fm/qLi3l).

Bladder cancer also has one of the highest recurrence rates among all forms of cancer, leaving about 600,000 people in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing this issue, and i/Blue demonstrations have indicated that the use of both white and blue light can enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates.

Based on Verified Market Research, the global bladder cancer research market was valued at $3.43 billion in 2018. It is estimated to grow with a CAGR of 4.03% through 2026, resulting in a projected $4.71 billion market (https://ibn.fm/rI7G6).

Management Team

E. James Hutchens is the Chief Executive Officer of Imagin Medical Inc. He is a proven entrepreneur with over 30 years of experience in management in the medical technology industry. Hutchens served as a managing partner with Origin Partners, a $55 million early-stage venture capital fund. He was also the founder and CEO of both Microsurge Inc. (a venture-backed minimally invasive surgical company) and Choice Therapeutics (an advanced wound-care company). He is a former member of the Board of Directors of the Brigham and Women’s and Faulkner hospitals. Hutchins holds a BS in Business Administration from Boston University.

John Vacha is the company’s Chief Financial Officer. He has 20 years of experience in the health care industry. Prior to Medtronic’s acquisition of Intact Medical Corp. in 2017, Vacha was the company’s President, CEO and a board member for seven years. He is a licensed CPA in Massachusetts. Vacha has an MBA and an MS in Accounting from Northeastern University in Boston. He is also a serving member of the Board of Directors at the South Boston Health Center. He currently has two patents in electrosurgical instrumentation.

Michael G. Vergano is the Director of Operations of Imagin Medical. He has been the President of The Harvest Group Inc. since 1998, where he has provided consultant services for startups and major corporations. Vergano has over 30 years of experience in the medical device industry. He has held management positions at Microsurge Inc., Ciba Corning Diagnostics and Boston Scientific Corp. He is currently the holder of 11 medical device patents and holds a BS in Mechanical Engineering from Tufts University.

Pam Papineau is the company’s Director of Regulatory Affairs. She has over 30 years of experience in quality and regulatory affairs with Boston Scientific, Baxter and Cogentix. She has served as a consultant on various devices including imaging, endoscopy, orthopedic, GI/GU and cardiovascular applications. Papineau has successfully prepared dozens of FDA pre-market and EU submissions to support CE marking of a broad spectrum of medical devices. She is an ASQ Certified Quality Engineer, a Certified Biomedical Auditor, a Certified Quality Auditor and an ISO 13485:2016 Lead Auditor, and she is certified by the Regulatory Affairs Professional Society – U.S., EU and Canada. Papineau works with the company’s legal counsel to prepare pre-submission meetings with the FDA and activities through the regulatory approval process.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), closed Friday's trading session at $0.44, up 5.8456%, on 11,800 volume with 19 trades. The average volume for the last 3 months is 6,596 and the stock's 52-week low/high is $0.200000002/$1.16999995.

Recent News

• Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) - Current Bladder Cancer Treatments May Adversely Affect Patients' Psychosocial Well-Being
• InvestorNewsBreaks - Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) to Demonstrate Advanced Capabilities of i/Blue Imaging System(TM) at AUA Annual Meeting
• FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF) Developing Tech Solutions for Carbon-free Ammonia Production, Renewable Energy Innovation

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

S&P Global Market Intelligence recently released a report that looked into greenhouse gas emissions in gold mines. The company analyzed sustainability reports for 2020, which were obtained from more than 90 leading gold mines in order to carry out a year-over-year comparison of emissions and determine the influence of the coronavirus lockdown on greenhouse gas emissions. The findings in the report may not be surprising considering that precious metals players such as Asia Broadband Inc. (OTC: AABB) are taking greater steps to limit emissions during their operations.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Friday's trading session at $0.1185, up 3.0435%, on 18,365,027 volume with 1,113 trades. The average volume for the last 3 months is 19.333M and the stock's 52-week low/high is $0.0026/$0.658999979.

Recent News

• Asia Broadband Inc. (OTC: AABB) - Report Finds Greenhouse Gas Emissions Didn't Increase at Gold Mines During Lockdown
• How Ocean Mining Could Play Out
• A "Time Lapse" View of the Silver Mining Steps

Grapefruit USA Inc. (OTCQB: GPFT)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit USA Inc. (OTCQB: GPFT).

Grapefruit USA (OTCQB: GPFT) understands that humans aren’t the only ones who may benefit from all that cannabidiol (“CBD”) has to offer and is positioning in a rapidly growing market. The pet CBD industry has experienced significant growth over the last several years, with the Brightfield Group projecting an expected market valuation of more than $1.7 billion by 2025 (https://cnw.fm/drv6i). Grapefruit is leveraging its expertise in the space with the launch of a new USDA-certified organic CBD pet tincture. To view the full article, visit: https://cnw.fm/iHzIv

Grapefruit USA Inc. (OTCQB: GPFT) is a Delaware corporation that is a fully licensed premier cannabis manufacturer and distributor in the legal cannabis marketplace with its own patented and branded line of products.

The company manufactures its patented product line and distributes it, along with other cannabis products, to all properly licensed cannabis product businesses.

Grapefruit is the only cannabis company that has harnessed cutting edge science and technology to bring patented, truly disruptive products to the medicinal and recreational cannabis marketplace, fundamentally changing the way individuals use THC, CBDs and hemp-derived CBDs and capitalizing on the rise in demand for these unique products.

Headquartered in Los Angeles, California, the company has held licensing in the state for manufacturing and distributing cannabis since 2018. Grapefruit currently owns and operates a California-licensed cannabis extraction laboratory and a licensed wholesale distribution facility in the Coachillin’ Canna-Business Park near Palm Springs, California. Grapefruit is managed by a team of experts who possess the experience, skills and resources required to succeed in the competitive cannabis marketplace.

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids.

Hourglass™ allows users to experience a sustained and holistic delivery of THC/cannabinoids providing “the entourage effect” following initial application to the skin. Additional applications may be made confidently and discreetly at the user’s discretion. There simply is no other product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that releases a holistic amount of THC, along with a wide range of cannabinoids (or just CBD), over a four- to eight-hour period.* The formula then comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

Hourglass™ provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) in a Patchless Patch™ system that is novel and proprietary to the company.

Hourglass™ Topical Delivery Cream has fundamentally changed the way individuals use THC and cannabinoids to obtain their holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the exclusive ways to receive both the medicinal and recreational benefits of THC/cannabinoids.* Now for the first time in history, there is an effective, easy to use third choice – Hourglass™ by Grapefruit.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.

Grapefruit Cannabis Services

Grapefruit distributes cannabis flower and cannabis products, including its own proprietary products, as well as a wide range of services, to other properly licensed cannabis product businesses. These products and services include:

• Distribution – As a premier licensed distributor, Grapefruit handles the distribution of all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from farms located in the state. The wholesale distribution arm facilitates flowers, fresh and dry frozen, and oil transactions in bulk wholesale form. Its wholesale distribution arm distributes its patented Hourglass™ topical delivery cream.
• Manufacturing – The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate. This THC Honey Oil distillate is a universal product used in everything, including infused edibles, tinctures, creams and even vape cartridges. Its patented Hourglass™ cream is also manufactured exclusively at Grapefruit’s Coachillin lab facility by highly trained Grapefruit personnel.
• Hourglass™ Topical THC+CBD Delivery Cream – The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a truly novel and disruptive delivery technology which fundamentally changes the way individuals will use THC and CBD to obtain their holistic benefits.*
• Rainbow Dreams – Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. The brand captures the party-mode of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.

Market Outlook

The global cannabis market was valued at $10.6 billion in 2018. During the forecast period from 2019 to 2026, the market is expected to grow at a CAGR of 32.92%, reaching a projected value of $97.35 billion by the end of 2026 (https://nnw.fm/eTMSX).

Cannabis legalization has been gaining momentum around the world. Grapefruit is currently in a position to disrupt the industry – both the medicinal and recreational sectors – with proprietary products and manufacturing processes that harness the power of cutting-edge science and technology.

Management Team

Bradley J. Yourist is the Chief Executive Officer of Grapefruit. Mr. Yourist has been a follower of the medical cannabis market since the late 1990s, which allows him to understand the distribution model and the legal issues facing the market. He has also seen the benefit of cannabinoids in the medical industry. He understands the planning and operations of Grapefruit’s cannabis distribution arm and extraction lab and was instrumental in the planning for the facility.

Daniel J. Yourist is the Chief Operating Officer of Grapefruit. He is a licensed attorney in the state of California and a Real Estate Broker. Mr. Yourist is a licensing expert in the cannabis space and has gained extensive experience in all areas of managing a cannabis business in California. He ensures that every aspect of the company is run in accordance with state and local cannabis laws and regulations.

Grapefruit USA Inc. (OTCQB: GPFT), closed Friday's trading session at $0.032, up 3.2258%, on 220,985 volume with 27 trades. The average volume for the last 3 months is 738,688 and the stock's 52-week low/high is $0.019999999/$0.310000002.

Recent News

• Grapefruit USA Inc. (OTCQB: GPFT) - CBDNewsBreaks - Grapefruit USA Inc. (GPFT) Committed to Creating High-Quality Products for Its Customers, Human or Otherwise
• 420 with CNW - Feds Finance Research into Use of Hemp as Ecofriendly Insulation
• 420 with CNW - States That Could Vote on Cannabis Legalization Measures in 2022

Hero Technologies Inc. (OTC: HENC)

The QualityStocks Daily Newsletter would like to spotlight Hero Technologies Inc. (OTC: HENC).

The cannabis plant produces more than 100 compounds, among them CBD, which has been found to possess medical benefits. CBD and THC are the two main compounds produced by the cannabis plant. THC, or tetrahydrocannabinol, is what gives cannabis its psychoactive properties while CBD, or cannabidiol, makes up the plants’ healing properties. Other cannabinoids produced by the plant include CBN (cannabinol), CBC (cannabichromene) and CBG (cannabigerol). With cannabis companies such as Hero Technologies Inc. (OTC: HENC) continuing to innovate, marijuana users are likely to see superior products leveraging the different attributes of many of the compounds in the cannabis plant as the years go by.

Hero Technologies Inc. (OTC: HENC) is a cannabis company with a vertically integrated business model and plan that includes cannabis genetic engineering, farmland for medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, retail operations and dispensaries that make the organization a multi-state operator (MSO).

The company was founded in 2004 and is headquartered in Dover, Delaware.

Portfolio

The company holds the majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation firm focused on providing optimal conditions to enhance photosynthesis and cultivation. Hero Technologies is planning expansion in cultivation and dispensary operations in Colorado through wholly owned subsidiary Mile High Green LLC, while expansion in Massachusetts is planned through another wholly owned subsidiary, MassCannabis LLC.

Hero Technologies also owns and operates HighlyRelaxing.com under Highly Relaxing LLC and recently acquired the assets of V Brokers LLC, now operating as Veteran Hemp Co. at VeteranHempCo.com.

BlackBox Systems and Technologies LLC

BlackBox Systems and Technologies LLC markets a proprietary cannabis aeroponic cultivation system designed for the large-scale production of top-shelf cannabis products. BlackBox offers the optimal conditions to enhance photosynthesis and promote the cultivation of large flowering plants. The system’s dry room, process room and secure storage were designed for precise control through each phase of the cannabis lifecycle. Weekly harvests are achieved using 13 separate BlackBox systems in independent modules.

The system provides a series of key benefits, including:

• High-pressure nutrient delivery, with no nutrient or PH deficiencies
• Sterile, 100% nutrient solution
• Drain to Waste (no reuse of wastewater)
• Low water usage (1 gallon per plant per day)
• Constant PH and EC in reservoirs
• Modular design (1 to 100 pods in any configuration)
• Innovative proprietary engineering
• Minimal cleanup
• Media-less growing, suspended in the air, with no media waste
• No pesticides

Highly Relaxing LLC

Highly Relaxing LLC is an emerging Henderson, Nevada-based operation dedicated to providing customers with honestly labeled, high-quality hemp-derived CBD products. Its current offerings include a topical CBD cream that provides localized relief from potential discomfort.

Veteran Hemp Co.

Veteran Hemp Co.’s mission is to provide a quality, consistent and delicious product for Americans looking to enjoy the hemp smoking experience. Its product is brought in by only the finest farming operations delivering the best genetics. Veteran Hemp Co. has its own custom harvest plans, drying facilities and all of the logistics that fall between. Veteran Hemp Co. prides itself on being a veteran-approved company.

Market Outlook

The global legal cannabis market is anticipated to reach $84 billion by 2028, expanding at a CAGR of 14.3% from 2021 to 2028. The driving factor for this forecast expansion is the increasingly widespread legalization of cannabis for medical and recreational use. Recreational use accounted for 60.3% of industry revenue in 2020.

North America provided the largest revenue share in the cannabis market, accounting for 91.1% of the global market in 2020. Due to the early legalization of medical and recreational cannabis in the region, the customer pool has increased exponentially (https://nnw.fm/snpHh).

The global CBD market was valued at $2.8 billion in 2020 and is expected to grow at a CAGR of 21.2% and reach $13.4 billion by 2028. North America is considered the most progressive region for cannabis and its derived products, with the highest number of CBD companies being based on the continent. The B2B (business to business) segment dominates the CBD industry, accounting for the largest revenue share at 59.6% in 2020 (https://nnw.fm/cGxXQ).

With its vertically integrated business model and development into a multi-state operator across multiple sectors of the cannabis industry, Hero Technologies is uniquely positioned to capitalize on the fast-growing market and the growing number of opportunities emerging as a result of legalization and increased popularity among consumers.

Management Team

Gina Serkasevich, CPA, CMA, is the Chief Executive Officer, Treasurer and Secretary of the Hero Technologies. She previously worked for Holloman Corporation as its Director of Finance beginning in June 2012 and was appointed Chief Financial Officer of Holloman Energy Corporation in August 2014. She has more than 30 years of domestic and international corporate accounting and finance experience. She served as U.S. Controller for EFLO Energy Inc., a company focused on the acquisition, exploration and development of oil and gas assets in North America. Prior to 2012, Ms. Serkasevich worked in the oil and gas tanker transportation industry as a Regional Financial Manager for AET Inc. Limited (2011-2012), as a Financial Consultant for OSG Ship Management Inc. (2009-2011) and as a Financial Controller/CFO for Stena Bulk LLC (1998-2008). During her 11-year tenure at Stena Bulk LLC, she established the financial, accounting and reporting requirements for its new joint ventures and tanker pools with Sonanagol USA and held the Company Secretary position on both of those companies’ boards of directors.

Dan McCarthy is the company’s Corporate Development Manager. He has spent more than 12 years in the institutional investment community, holding various investment banking and private equity executive roles. Thus far, he has been a part of over $1 billion in transactional value ranging from debt and equity to acquisitions and diversities throughout his career. Mr. McCarthy’s most recent role was Managing Director at Petro Capital, a Dallas-based private equity and investment bank. He began his career working for a private international consulting firm based in Washington, D.C., helping corporations and funds expand into non-G7 countries utilizing World Bank financing. He is also a graduate of the University of Kansas School of Business and completed the Mergers and Acquisitions program at the New York Institute of Finance.

James Rowland is Hero Technologies’ Marketing Advisor and an expert in marketing and e-commerce. He has held many high-level marketing and business-related roles. He is the Founder and current CEO of PerfectCheckout.com and the current Business Development Specialist at Fulfillment.com. Mr. Rowland has held multiple high-level positions throughout his career, which have provided him with the experience needed to bring success-backed marketing leadership skills to his current role with the company.

Hero Technologies Inc. (HENC), closed Friday's trading session at $0.06, even for the day, on 338,409 volume with 27 trades. The average volume for the last 3 months is 180,419 and the stock's 52-week low/high is $0.0236/$0.317400008.

Recent News

• Hero Technologies Inc. (OTC: HENC) - 420 with CNW - How CBG Differs from CBD Oil
• 420 with CNW - Cannabis Pipe Makers Gain Recognition As Cannabis Legalization Wave Spreads
• 420 with CNW - SAMHSA Funding Restrictions Eased in Relation to Medical Marijuana

Lottery.com

The QualityStocks Daily Newsletter would like to spotlight Lottery.com.

Trident (NASDAQ: TDAC, TDACU, TDACW), a special purpose acquisition company, previously announced its entry into a definitive agreement with AutoLotto Inc. (doing business as “Lottery.com”), a leading platform to play the lottery online. The agreement allows Lottery.com to become a publicly listed company. Trident today announced that it has filed an updated investor presentation with the Securities and Exchange Commission (“SEC”) in connection with its business combination with Lottery.com. The presentation includes, among other things, positive updates to peer valuation metrics and reiterates Lottery.com’s strong financial outlook and 2021 financial projections. The outlook is supported by strong preliminary second quarter 2021 results announced in early August. Lottery.com achieved sequential revenue growth averaging approximately 87% per quarter during the last four quarters ended June 30, 2021. The company expects similar average growth in the near term as well as additional tailwind to revenue growth from the acquired interests in JuegaLotto and Aganar. To view the full press release, visit https://ibn.fm/zBYHu

Lottery.com is a next generation platform where consumers can play the lottery online – in browser or via smartphone app. The platform offers users access to official lottery games sanctioned by their individual states and also provides lottery data to more than 400 digital publishers, including Google and Amazon Alexa.

Lottery.com was founded in 2015, launching at the LAUNCH festival and soon turning into a leader in the industry. With headquarters in Austin, Texas, the company is dedicated to helping advance the lottery industry into the digital age and works closely with state regulatory bodies to achieve this goal.

The company recently entered into a definitive agreement for a business combination with special purpose acquisition company Trident Acquisitions Corp. (NASDAQ: TDAC) (“Trident”), which will result in Lottery.com becoming a publicly listed company. Once the transaction is complete, the combined company will be trademarked as Lottery.com, with its common stock to remain listed on Nasdaq under ticker symbol ‘LTRY’.

Lottery.com Online Platform

The Lottery.com online platform works closely with state regulators, advancing the lottery into the digital age. With the online platform, the company offers enhanced regulatory capabilities by leveraging innovative blockchain technology and capturing the untapped market of digitally native players.

Players go online in a browser or through a mobile application to use the interface. The process includes:

• Players Choose a Game: Players can play officially state sanctioned multi-state games and other games offered in the states in which they live. Players can also find winning numbers, jackpot totals, draw dates and more for hundreds of other lottery games around the world.
• Players Pick Numbers: Players can play their lucky numbers or do a quick pick of randomized numbers in as simple as two taps. “Tap, Tap, Ticket!”
• A Safe and Secure Way to Play: Purchases for up to 50 tickets can be made at one time through the online interface. Lottery.com handles everything after purchase, letting users know when they win.
• Collect All Winnings: Consumers keep 100% of their winnings. All winnings stay in the Lottery.com balance for future ticket purchases, or a cashout can be requested. Company representatives contact winners who hit big jackpots, instructing them on the redemption process.

A Better Way to Play the Lottery

Lottery.com has an innovative e-commerce platform that is using blockchain to maintain an accurate ledger. From 2016 to 2020, Lottery.com grew gross revenue at a CAGR of 363%, and it forecasts gross revenue equal to approximately $71 million in 2021, $279 million in 2022, and $571 million in 2023.

Lottery.com is leveraging a successful playbook, with $398 billion in global lottery sales but only 6.7% online penetration. The large market opportunity is expected to shift to online transactions within the next decade.

The platform is currently available in 12 states across the United States, and the company plans to expand to 34 by the end of 2023. Global expansion is also on the horizon, with partnership plans in Turkey and Ukraine.

Key features that make the Lottery.com experience unique include:

• All the Games Users Love – For consumers who live in applicable LIVE states, Powerball and Mega Millions are available right from the mobile application.
• Convenience – Lottery.com makes playing the lottery on mobile devices easy. After setting up an account, users can begin playing in moments or set reminders to play when the jackpot is high.
• Easy Cashouts – Users can cash out winnings straight to a bank account, safely and securely, with no commissions.

The company is also gamifying charitable giving, fundamentally changing how nonprofits engage with donors and raise funds. WinTogether.org is a platform designed to offer charitable donation sweepstakes to incentivize donors to take action by offering large cash prizes and once-in-a-lifetime experiences.

Strong Advisory Board Presence

Lottery.com is expected to continue to gain support, leaning on the experience of its advisory board and notable investors from the venture capital, gaming and entertainment industries. These include:

• Jason Robins, CEO of DraftKings Inc. (NASDAQ: DKNG)
• Ben Narasin, Venture Partner of NEA
• Peter Diamandis, Chairman of XPRIZE Foundation
• Matthew Le Merle, Co-Founder and Managing Partner of Fifth Era and Keiretsu Capital
• Paraag Marathe, President of Enterprises and EVP of Football Operations for the San Francisco 49ers
• Jamie Gold, The Poker Philanthropist

Management Team

Tony DiMatteo is the Co-Founder and Chief Executive Officer of Lottery.com. He is a serial entrepreneur and highly sought-after industry speaker and thought leader. He has been featured in The Wall Street Journal, Forbes, VentureBeat, TechCrunch Inc. and more for his approach to entrepreneurship, the gaming industry and cryptocurrency.

Matt Clemenson is the Co-Founder and Chief Commercial Officer of Lottery.com. He is responsible for the company’s strategy. Mr. Clemenson was steeped in corporate and enterprise engineering processes at Hotwire and Expedia before going on to be CEO at LesConcierges, the world’s largest concierge company, which merged into John Paul and sold to Accor Hotels. Clemenson and DiMatteo have been partners for more than 10 years.

Ryan Dickinson is the company’s President and Chief Operating Officer. He has a diverse background in business, technology, product, design and sales, which has aided him in producing many successful outcomes throughout his career. Notably, as Senior Vice President of a SaaS company, Mr. Dickinson produced profitability from a negative $1.4 million division within the first year by reinventing the product offerings, streamlining processes and establishing a go-to-market strategy. Additionally, he produced three record breaking revenue years in a row for AccuWeather, the world’s largest weather provider, by increasing every KPI for all flagship properties by no less than 5%.

Luc Vanhal is the company’s Chief Financial Officer. He has served in C-level executive roles since the 1990s, including a nine-year tenure for The Walt Disney Company (NYSE: DIS) from 1990 to 1999. From 2001 to 2004, he managed the development of the World of Warcraft massively multiplayer game, which, by the end of 2020, still had over five million active subscribers. As the CFO of Lottery.com, Mr. Vanhal leads the company’s global finance organization, with treasury responsibility, accounting, analysis and financial planning.

Recent News

• Lottery.com - InvestorNewsBreaks – Trident Acquisitions Corp. (NASDAQ: TDAC) Files Updated Investor Presentation for Business Combination with Lottery.com
• InvestorNewsBreaks – Lottery.com Partners with Coinstar to Offer Lottery Games Across the US
• InvestorNewsBreaks – Trident Acquisitions Corp.’s (NASDAQ: TDAC) Pending Business Combination Partner Lottery.com Announces Corporate Update, Preliminary Q2 2021 Results

Sustainable Green Team Ltd. (SGTM)

The QualityStocks Daily Newsletter would like to spotlight Sustainable Green Team Ltd. (SGTM).

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, and its portfolio of subsidiaries specialized in tree services, debris hauling, biomass recycling, and manufacture of next-generation mulch products and cypress lumber, have the necessary expertise to deal with storms and their negative impact. According to a recent article, SGTM’s vertically integrated operations include three brands “that speak quite clearly to the corporate mission to reduce environmental impact through responsible handling of tree debris rather than burying it in already over-burdened landfills.” The process is efficient and green. “From a mobile command center assessing the damage and plotting a clean-up strategy to truck and rail logistics to create and move feedstock to one of its six production facilities to its retail and wholesale end consumers, SGTM can handle it all.” To view the full article, visit https://ibn.fm/pHycC

Sustainable Green Team Ltd. (OTC: SGTM), through its subsidiaries, including National Storm Recovery LLC (DBA Central Florida Arbor Care and Mulch Manufacturing Inc.), provides tree services, debris hauling, removal and bio-mass recycling, manufacturing, packaging and sales of next-generation mulch products. The company’s primary corporate objective is to provide a solution for the treatment and handling of tree debris that is historically sent to local landfills and disposal sites, creating an environmental burden and pressure on disposal sites around the nation.

Environmentally Friendly

SGTM and the solutions provided by its Sustainable Green Team are founded in sustainability. The company’s vertically integrated operations begin with the collection of tree debris through its tree services division and collection sites. Tree bio-mass is then moved through the processing division for recycling and manufacturing into a variety of organic, attractive, next-generation mulch products to be packaged and sold to retailers, landscapers, installers and garden centers.

The company’s solutions create a synergistic and environmentally beneficial solution to tree and storm waste disposal that historically has created an environmental burden on landfills and disposal sites around the nation.

SGTM’s customers include governmental, residential and commercial customers and now big box retailers. The company is headquartered in Florida.

Strategic Acquisition

SGTM in February 2020 acquired 35-year-old industry leader and innovator Mulch Manufacturing Inc., an Ohio corporation. Structured as a share exchange, this strategic partnership provides SGTM with a significantly larger footprint in the mulch industry.

The acquisition includes Mulch Manufacturing’s national and international distribution agreements, an increase in production and packaging capacity, and its sales contracts with numerous big box retailers. Mulch Manufacturing includes mulch production, sawmill operation, Natures Reflections colorant manufacturing and equipment manufacturing.

Next-Gen Products

SGTM’s vision and commitment to the environment is paired with Mulch Manufacturing’s revolutionary “next-generation” mulch product, Nature’s Reflection’s Softscape®.

Softscape mulch products, created from natural forest products, are color-enhanced with environmentally safe colorants to provide four-year color retention and are free from contaminants. Safe for people and pets, Softscape allows water and air to penetrate soil and roots, which is vital to plant health and growth.

Expansion Plans

SGTM plans to expand its operations through a combination of organic growth, through its partnership with a nationally recognized waste disposal company, and through strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified.

The company has received final zoning approval for its 100-acre site, located in Lake County, Astatula, Florida, which will serve as its flagship tree debris collection site. The facility will also house the company’s mulch manufacturing, soil composting and production bagging. This prime location includes a 5,000-square-foot building that contains warehouse and office space. The 100-acre property can accommodate millions of cubic yards of organic debris and will allow SGTM’s debris hauling division to realize significant savings on its transportation costs.

SGTM has chosen as its new headquarters the 100,000-square-foot Mulch Manufacturing building in Jacksonville, Florida. The facility comprises centralized operations of Mulch Manufacturing Inc. and National Storm Recovery LLC and has ample room to expand as needed.

Leadership

SGTM’s leadership team boasts more than 40 years of next-level experience with mulch manufacturing, treating and caring for trees. This team is guided by a roster of highly qualified professionals:

• Tony Raynor, Chief Executive Officer
• Edward Lee, Chief Operating Officer
• Ralph Spencer, Director of Business Development, Strategic Acquisitions
• Steve Ogden, ISA-Certified Arborist
• Rick Starcher, Master Chemist
• Peder K. Davisson, Esq., Corporate/Securities Counsel

Sustainable Green Team Ltd. (OTC: SGTM), closed Friday's trading session at $1.06, off by 12.3967%, on 895 volume with 6 trades. The average volume for the last 3 months is 923 and the stock's 52-week low/high is $0.200000002/$7.00.

Recent News

• Sustainable Green Team Ltd. (OTC: SGTM) - InvestorNewsBreaks - Sustainable Green Team Ltd. (SGTM) Offering Efficient Solutions Before and After Storms
• InvestorNewsBreaks - Sustainable Green Team Ltd.'s (SGTM) Solutions Are Rooted in Sustainability, Vertically Integrated Operations
• InvestorNewsBreaks - Sustainable Green Team Ltd. (SGTM), Subsidiary Poised to Deal with Severe Storms, Aftermath

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, was featured in a recent equity research report. The coverage, initiated by Ladenburg Thalmann & Co. Inc., highlights Tryp Therapeutics’ efforts to reset the treatment of various disorders through the novel dosing of formulations of synthetic psilocybin. “We are initiating coverage on Tryp Therapeutics with a Buy rating and $2.00 price target based on our research into its psychedelic-based pipeline, which is leveraging psilocybin’s potential to treat patients with inadequately addressed neurological disorders. To view the full report, visit https://ibn.fm/LOngF.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Friday's trading session at $0.3968, off by 0.301508%, on 282,780 volume with 89 trades. The average volume for the last 3 months is 105,975 and the stock's 52-week low/high is $0.322299987/$1.03999996.

Recent News

• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report
• What To Know Before Investing in the Psychedelic Industry
• Four Fungi Facts Revealed by Netflix Psychedelics Documentary

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with its FDA-cleared NeuroCap(TM) and NeuroEEG(TM), which are already patented in the United States, China and Europe. As the company’s first commercialized devices, they are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. To view the full article, visit: https://ibn.fm/1sVpj

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

• NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

• NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

• NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
• NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

• Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
• An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Friday's trading session at $0.35, off by 6.6667%, on 10,389 volume with 3 trades. The average volume for the last 3 months is 24,820 and the stock's 52-week low/high is $0.116099998/$1.95000004.

Recent News

• Brain Scientific Inc. (OTCQB: BRSF) - BioMedNewsBreaks - Brain Scientific Inc. (BRSF) Modernizing, Increasing Accessibility to Brain Diagnostics
• Molecular Approaches May Help Accurately Diagnose Lesions in Drug-Resistant Focal Epilepsy
• BioMedNewsBreaks - Brain Scientific Inc. (BRSF) Tapping into AI, ML Technology to Facilitate Early Diagnosis of Brain Disorders

DSG Global Inc. (OTCQB: DSGT)

The QualityStocks Daily Newsletter would like to spotlight DSG Global Inc. (DSGT).

America’s green-energy goals recently became clearer after President Joseph Biden announced a new national target for electric vehicles (“EVs”) that would require one-half of U.S. vehicle sales to be electric by 2030. It is part of the Biden administration’s efforts to cut down the country’s reliance on fossil fuels and reduce greenhouse-gas emissions by replacing conventional internal combustion engines (“ICE”) with zero-emission electric vehicles. With the effects of climate change becoming increasingly clear across the country, eliminating carbon emissions is becoming a matter of life and death. Electric scooters can play a vital role on the last mile of people’s commutes, and companies such as DSG Global Inc. (OTCQB: DSGT), which have entered the sector to distribute these two-wheelers are likely to help attain the desired goal of electrification of travel.

DSG Global Inc. (OTCQB: DSGT) is an emerging global technology company with interconnecting businesses in fast growing market sectors. With roots in the golf industry, the company specializes in golf fleet management and is moving quickly into road-ready electric vehicles for delivery in the third quarter of 2021.

In 2019, the company secured exclusive North America distribution rights for Jonway Automobile Co. road-ready electric vehicles (EVs). Jonway, based in Zhejiang, China, began manufacturing new vehicles s in 2003 and today produces Electric powered Cars, Trucks, Vans, SUV’s, and Scooters. Jonway vehicles are exported to more than 80 countries and are built to comply with U.S. safety and environmental standards.

These vehicles are being sold via DSG’s wholly owned subsidiary, Imperium Motor Company (IMC). The move into consumer vehicles capitalizes on the company’s strength in the selection and distribution of EVs, the ability to work with large manufacturers and in application of proprietary technology unique to DSG. DSG’s advanced fleet tracking can be integrated into Jonway EVs to offer a customized scalable and integrated solution to meet the needs of small businesses and large enterprises.

The Future is Electric

With decades of EV experience in golf, including distribution of highly advanced carts, DSG recognized the huge chasm between consumer interest in acquiring road ready EVs versus current EV models’ lack of availability and affordability. As such, the company focused on becoming a distribution and EV brand management company unencumbered by the manufacturing process. The manufacturers take responsibility for building vehicles to DSG’s specifications and fulfillment of regulatory and licensing requirements.

DSG has also established a distribution agreement with Skywell New Energy Automobile Group Ltd., an Asian-based EV manufacturer. Skywell will supply DSG with SUV’s, Passenger Vans, Cargo Vans, Commercial Vehicles and Buses that will be fully certified for use in the United States.

Brands

Imperium Motor Company (IMC) seeks to transform the way the world drives by making greener transportation available to everyone. IMC is an EV sales and marketing company that distributes directly to consumers and through third party distributors, offering a wide variety of affordable vehicles equipped for the North American market. The company’s emphasis is on great design, a green mindset, performance and functionality. Its vehicles include 26 models of high-speed, mid-speed and low-speed electric vehicles including cars, trucks, SUVs, vans, buses and scooters.

Vantage Tag Systems (VTS) is a global leader in the design, manufacture, and marketing of fleet management solutions for the golf industry. VTS has developed the TAG suite of products that represents the industry’s first completely modular fleet management solution. The company’s patented analytics, mobile touch screen GPS units and electric golf carts are sold around the world through a network of established distributors and partnerships with notable brands in fleet and equipment manufacture. VTS solutions also have applications in managing commercial, agricultural, military and government fleets. VTS is a wholly owned subsidiary of DSG Global.

Market Outlook

The global EV market was valued at $273 billion in 2017, according to Fortune Business Insights, and is projected to exceed $987 billion by 2027, with a projected CAGR of 17.4 percent. The relative high manufacturing costs of EVs compared to gasoline-powered vehicles and the resulting higher sticker price to consumers are major obstacles to near term market adoption.

The global e-bike market is estimated to grow to $70 billion by 2027 from its current valuation of $41.1 billion. An estimated 130 million e-bikes are expected to be sold globally over the next two years. The U.S. imported approximately 600,000 e-bikes in 2020, according to the Light Electric Vehicle Association, and its analysts expect that number will grow substantially in 2021.

Management Team

Robert “Bob” Silzer is the CEO of DSG Global. He is a serial entrepreneur who turns technology ideas in high growth industries into profitable businesses. With roots in the golf industry, he founded Vantage Tag Systems in 2008. Vantage Tag Systems is now a DSG subsidiary specializing in GPS-enabled fleet management.

Zahir Loaiza is the interim CFO of DSG Global. She assumed the role in March 2021, after having previously served as the company’s Corporate Controller. Her diverse international experience includes working at a publicly traded mining company, several law firms and more in the U.S., Canada and South America. Prior to pursuing a career in corporate finance, she was the owner of two retail entities.

Rick Curtis is the president and COO of Imperium Motor Company, the automotive subsidiary of DSG Global. His 40-year background in the automotive industry includes manufacturing, vehicle distribution, parts distribution, service management, dealer development and executive management of dealer groups. Prior to joining Imperium, Mr. Curtis served as president of Mullen Technologies and grew the company into a world class provider of electric vehicles, battery technology and energy storage systems.

William “Bill” Rex is president of Imperium Motor’s EV Bus and Motor Home Division. He has more than 40 years’ experience at suppliers of buses/electric buses, motor homes, trucks, specialty vehicles and batteries. He is the founder of Rexhall Industries Inc., formerly a publicly traded manufacturer of RVs and distributor of buses and coaches. He previously served as president of THOR West, a subsidiary of THOR Industries that manufactures shuttle buses, and as president of BYD Coach and Bus.

Patrick J. Parenti is the SVP Global Sales at DSG subsidiary Vantage Tag Systems. He has nearly 30 years of experience in golf and golf course management. Prior to joining DSG in 2012, Mr. Parenti served for 10 years as SVP at ProLink Systems, a leading global provider of GPS golf-course management systems.

Clint Singer is Director of Engineering at Vantage Tag Systems. He has been a senior developer in the golf industry for more than 20 years and has an extensive background in GPS systems.

Daniel Price is Technical Operations Manager of DSG Global’s European Region, UK, South Africa. In addition to his background in mechanical and electronic engineering, he is an audio engineer, specializing in automotive audio and security. He has also worked with high end electronic security companies in the UK and previously owned an electronic security and CCTV company.

Steven Mueller is Operations Manager at Vantage Tag Systems. He worked in the global pulp and paper market for nine years, facilitating the global movement of thousands of tons of timber products annually. Additionally, he has a successful decades-long track record of managing operations and consulting for a wide range of retail businesses.

DSG Global Inc. (DSGT), closed Friday's trading session at $0.15, off by 3.599%, on 1,092,721 volume with 139 trades. The average volume for the last 3 months is 685,879 and the stock's 52-week low/high is $0.0251/$1.51999998.

Recent News

• DSG Global Inc. (OTCQB: DSGT) - East Bronx Launches Electric Scooter Sharing Program
• Five Top Benefits of EV Fleet Management Solutions
• InvestorNewsBreaks - DSG Global Inc. (DSGT) Issues Wholesale Importer Sales Update Towards Achieving Large-Scale Distribution